Medicaid Guidance Aims To Help States Save Money With Biosimilars

CMS released strategies for states to save money with biosimilars Monday (March 30) that include placing biosimilars on preferred drug lists in return for drug companies offering extra rebates. The Affordable Care Act created the approval path for biosimilars, but FDA didn't approve the first biosimilar until earlier this month. “In addition to the rebates received from manufacturers, cost savings may be achieved through the establishment of supplemental rebate agreements between states and manufacturers,” the notice says. “States may consider...